TP53 and head and neck squamous cell carcinoma: Several pre-clinical studies have suggested that AZD1775 potentiates the activity of various chemotherapeutic agents [10–15], including cisplatin-induced G2/M arrest in HNSCC TP53 mutant cell lines [16].